Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas

Current Status: Site-Specific Antibody Drug Conjugates

(2016) Dominik Schumacher et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

(2015) Roger R. Beerli et al.   PLoS One

Particle generation, functionalization and sortase A–mediated modification with targeting of single-chain antibodies for diagnostic and therapeutic use

(2014) Christoph E Hagemeyer et al.   Nature Protocols

Methods to Make Homogenous Antibody Drug Conjugates

(2014) Toni Kline et al.   PHARMACEUTICAL RESEARCH

Novel Conjugation of Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Monomethyl Auristatin E for Efficient Antitumor Drug Delivery

(2013) Li-Qiang Pan et al.   ADVANCED MATERIALS

Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)

(2013) Li-Qiang Pan et al.   BIOMATERIALS

Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin

(2013) Zhao Hui Li et al.   INVESTIGATIONAL NEW DRUGS

Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin

(2013) Petra Kornberger et al.   mAbs

Site-specific N-terminal labeling of proteins using sortase-mediated reactions

(2013) Christopher S Theile et al.   Nature Protocols

Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes

(2013) Lee Kim Swee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

(2012) G. Salles et al.   BLOOD

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Anti-CD20 Antibody Therapy for B-Cell Lymphomas

(2012) David G. Maloney   NEW ENGLAND JOURNAL OF MEDICINE

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

In vitro Sortagging of an Antibody Fab Fragment: Overcoming Unproductive Reactions of Sortase with Water and Lysine Side Chains

(2011) Sina Möhlmann et al.   CHEMBIOCHEM

A general strategy for the evolution of bond-forming enzymes using yeast display

(2011) I. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies

(2010) Bruce D. Cheson   JOURNAL OF CLINICAL ONCOLOGY

CD19: a promising B cell target for rheumatoid arthritis

(2009) Thomas F. Tedder   Nature Reviews Rheumatology

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY